Core Viewpoint - Tianfeng Securities maintains an "overweight" rating for Hansoh Pharmaceutical, adjusting revenue and net profit forecasts for 2025, 2026, and 2027 due to expected large BD transaction payments [1] Group 1: Financial Performance - The revenue forecast for 2025 is raised from 137.41 billion to 146.68 billion RMB, with expected revenues of 158.35 billion and 177.79 billion RMB for 2026 and 2027 respectively [1] - The net profit forecast for 2025 is increased from 47.46 billion to 51.67 billion RMB, with expected net profits of 53.25 billion and 61.33 billion RMB for 2026 and 2027 respectively [1] - In the first half of 2025, total revenue reached 74.34 billion RMB, with a net profit of 31.35 billion RMB [1] Group 2: Product Performance - Revenue from innovative drug products reached 61.45 billion RMB, accounting for 82.7% of total revenue [1] - The metabolic and other fields saw significant growth, with revenue from this segment approximately 14.00 billion RMB, a year-on-year increase of 134.5% [1] - The anti-tumor product portfolio, including Amatinib and Flumatinib, generated revenue of 45.31 billion RMB, remaining stable year-on-year [1] Group 3: Innovation and Clinical Development - Over 40 candidate innovative drugs are undergoing more than 70 clinical trials, with 8 new drugs entering clinical trials in the first half of 2025 [3] - Three drugs have entered Phase III clinical trials, including HS-20137 for psoriasis and HS-20093 and HS-20089 for sarcoma and ovarian cancer respectively [3] - The TYK2 inhibitor HS-10374 is also in Phase III trials, showing low skin toxicity risk [3] Group 4: Market Position and Growth - Amatinib, as the first domestic third-generation EGFR TKI, has seen rapid sales growth, with a compound annual growth rate of 214% from 2020 to 2024 [2] - Amatinib is expanding its indications related to NSCLC, with four approved indications and additional ones expected in 2025 [2] - The drug received approval from the UK MHRA in June 2025, marking Hansoh's first entry into the overseas market [2]

Core Viewpoint - Tianfeng Securities maintains an "overweight" rating for Hansoh Pharmaceutical (03692), adjusting the 2025 revenue forecast from 13.741 billion to 14.668 billion RMB, with expected revenues of 15.835 billion and 17.779 billion RMB for 2026 and 2027 respectively. The net profit forecast for 2025 is raised from 4.746 billion to 5.167 billion RMB, with projections of 5.325 billion and 6.133 billion RMB for 2026 and 2027 respectively [1] Group 1 - In H1 2025, the total revenue of the company reached 7.434 billion RMB, with a net profit of 3.135 billion RMB. Revenue from innovative drug products amounted to 6.145 billion RMB, accounting for 82.7% of total revenue [1] - The revenue from the metabolic and other fields saw significant growth, with the MSD upfront payment received [1] - In H1 2025, the product portfolio in the oncology field, including Amivantamab and Furmonertinib, generated revenue of 4.531 billion RMB, remaining stable year-on-year [1] Group 2 - The sales of Amivantamab, the first domestic third-generation EGFR TKI, have rapidly increased, with a compound annual growth rate of 214% from 2020 to 2024, reaching 1.784 billion RMB in 2024 [2] - Amivantamab has expanded its indications related to NSCLC, with four approved indications and additional approvals expected in 2025 [2] - The company aims to obtain EMA recognition for Amivantamab in overseas markets following its approval by the UK MHRA in June 2025 [2] Group 3 - The company has over 40 candidate innovative drugs undergoing more than 70 clinical trials as of H1 2025 [3] - Eight new innovative drugs entered clinical trials in H1 2025, including HS-20122 (EGFR/c-Met ADC) and HS-10510 (PCSK9) [3] - Three new drugs entered Phase III clinical trials, including HS-20137 (IL-23p19) for psoriasis and two ADCs for bone and soft tissue sarcoma and ovarian cancer, with overseas rights granted to GSK [3]

Group 1 - The core viewpoint of the report is that Tongwei Co., Ltd. is rated as "Buy" due to its strong position in the power supply industry, particularly in the UPS power supply business for computing centers and data centers, which contributes significantly to its profits [1] - The industry outlook indicates that the demand for UPS batteries is expected to grow significantly driven by AIDC, and there is a broad long-term application space for hydrogen energy in data centers [1] - The company has a diversified approach in the computing center and data center UPS power supply market, with a multi-line layout including lithium batteries, lead-acid batteries, and hydrogen energy [1]

Group 1 - The core viewpoint of the report indicates that Xinlitai's net profit attributable to shareholders for the first half of the year is 365 million yuan, representing a year-on-year growth of 6.10% [1] - In Q2 2025, the net profit attributable to shareholders is 165 million yuan, showing a year-on-year increase of 14.55% [1] - The approval and launch of two hypertension drugs are timely, and multiple pipelines are expected to enter a harvest period [1] Group 2 - Sales growth from patented and new products has become the core pillar of the company's performance [1] - The new diabetes drug Xinlitai has rapidly gained market share due to its inclusion in the national medical insurance catalog [1] - Significant revenue increases have been observed for the renal anemia drug Ennaruo and the orthopedic drug Xinfu Tai [1] Group 3 - Key research projects are progressing smoothly, with the listing applications for Ennadustat (anemia indication for CKD patients on dialysis) and SAL056 (long-acting teriparatide) currently under review by CDE [1] - The Phase III trial for S086 in chronic heart failure has completed patient enrollment, and the PCSK9 monoclonal antibody SAL003 has completed Phase III clinical research, achieving primary endpoints for both monotherapy and combination therapy with statins [1] - It is expected that the listing applications will be submitted within the year [1] Group 4 - Additionally, early clinical stages are underway for the aldosterone synthase inhibitor SAL0140 (for uncontrolled hypertension) and the broad-spectrum anti-tumor innovative biological drug JK06 [1] - In the second half of the year, 3 to 4 projects in cardiovascular and metabolic fields are anticipated to advance to the IND stage [1] - The report maintains a "buy" rating for the company [1]

Group 1 - The core viewpoint of the report indicates that the company achieved a revenue of 900 million in Q2 2025, representing an 8% year-on-year increase, and a net profit of 200 million, which is a 16% increase compared to the previous year [1] - For the first half of 2025, the company reported a revenue of 1.7 billion, marking an 11% year-on-year growth, and a net profit of 300 million, reflecting a 22% increase [1] - The primary sales category driving growth in overseas markets remains the leisure turf segment, with sales volume increasing by 8.69% and revenue growing by 11.23% year-on-year [1] Group 2 - The Americas and Europe are identified as the main sources of growth in overseas markets during the first half of the year [1] - The company's foreign trade sales department has enhanced market-driven and customer value-driven strategies, including increasing customer visit frequency and actively participating in international exhibitions to strengthen customer relationships [1] - Despite ongoing global trade tensions and geopolitical conflicts that have slowed economic growth, the company's management remains focused on "change and breakthrough," achieving stable growth in overseas market revenue and profits [1] Group 3 - The company has adjusted its profit forecast and maintains a "buy" rating for its stock [1]

Core Viewpoint - Tianfeng Securities report indicates that Yanjinpuzi's revenue and net profit attributable to shareholders for H1 2025 are projected to be 2.941 billion and 373 million yuan, respectively, representing year-on-year growth of 19.58% and 16.70% [1] Group 1: Financial Performance - For Q2 2025, the revenue and net profit attributable to shareholders are expected to be 1.403 billion and 195 million yuan, with year-on-year increases of 13.54% and 21.75% respectively, and a 32% increase in non-recurring net profit [1] - The company is adjusting its earnings forecast due to ongoing adjustments in direct sales and e-commerce channels [1] Group 2: Strategic Outlook - The company is expected to continue its high growth in performance, driven by its dual-driven growth model of "products + channels" and its long-term strategy of "multi-brand, multi-category, all-channel, full industry chain, and future globalization" [1] - The revenue projections for 2025 to 2027 are estimated at 6.3 billion, 7.5 billion, and 8.9 billion yuan respectively, maintaining a "buy" rating [1]

Core Viewpoint - The overseas computing power industry chain remains highly prosperous and is not impacted by DeepSeek and trade frictions, with stronger fundamental resonance in the related industry chain [1] Group 1: AI Industry Outlook - The AI industry is viewed as a key investment theme for the year, with expectations for significant developments in domestic AI infrastructure and applications by 2025 [1] - Continuous progress is noted in both China and the US AI sectors, particularly in inference capabilities [1] - The report emphasizes the importance of monitoring AI industry dynamics and investment opportunities in AI applications [1] Group 2: Domestic and Overseas Opportunities - The government work report has included "deep-sea technology" for the first time, indicating a positive trend for the deep-sea cable industry starting in 2025 [1] - There is a strong recommendation to focus on core investment opportunities in "AI + overseas expansion + satellites," particularly in overseas AI sectors such as optical modules, liquid cooling, and domestic computing power lines like servers and switches [1] - The domestic industry is experiencing a recovery, while overseas expansion presents good opportunities, with a focus on leading companies in the submarine cable sector [1] Group 3: Satellite Internet Industry - Recent developments in the domestic satellite internet industry are noted, with optimism for future growth driven by industry catalysts [1]

Core Viewpoint - The report from Tianfeng Securities highlights that Xiongtao Co., Ltd. is a veteran in the power supply industry, with its computing center and data center UPS power supply business contributing significantly to its profits. [1] Revenue Contribution - In the first half of 2025, revenue from the computing center and data center UPS power supply business is expected to account for 47% of the company's total revenue, contributing 75% of its profits. [1] Market Trends - The demand for AI computing power is rapidly increasing, leading data centers to evolve towards large-scale, high-density, and high-power configurations. [1] Product Advantages - Lithium battery products offer advantages such as long lifespan, high energy density, and environmental benefits. Compared to lead-acid batteries, lithium batteries have a significant cost advantage over their entire lifecycle, potentially saving over 40% in total ownership costs within 10 years. [1] Strategic Positioning - The company is deeply engaged in the UPS business for computing centers and data centers, with a diversified product line including lithium, lead-acid, and hydrogen energy solutions. [1] Investment Outlook - Given the company's strong positioning in the UPS business, it is expected to benefit from investments in AI data centers, leading to an initial coverage rating of "Buy." [1]

天风证券（601162）发布研报称，维持特步国际(01368)"买入"评级，考虑到下半年消费环境仍有所承 压以及索康尼盈利提升，调整盈利预测，预计公司25-27年收入146亿人民币、154亿人民币、165亿人民 币(原值为147亿人民币、158亿人民币、170亿人民币);归母净利14.0亿元、15.2亿人民币、17.0亿人民币 (原值为13.6亿元、15.2亿人民币、16.9亿人民币)。 户外方面，公司拓展产品矩阵，推出两款高性能产品，分别是"飞石"徒步鞋及涼鞋，以及"山猫"越野跑 鞋。篮球方面，品牌代言人林书豪在沈阳开展一系列活动，包括特步沈阳店的开业、门店签售活动，以 及东北大学互动篮球赛;此外，特步还成为第七届亚洲大学生三对三篮球锦标赛赛事指定转杯赞助商。 公司发布2025中报。25H1：持续经营业务之收入68亿，同比+7%，特步主品牌收入61亿，同比+5%， 专业运动分部收入7.9亿，同比+33%。25H1持续经营业务之经营溢利13亿，同比+9%，专业运动分部的 经营溢利0.8亿，同比大幅增长237%。已终止经营业务(K SWISS和帕拉丁)于2024年上半年亏损1.1亿人 民币后，25H1公司普通股 ...

公司发布2025中报。25H1：持续经营业务之收入68亿，同比+7%，特步主品牌收入61亿，同比+5%， 专业运动分部收入7.9亿，同比+33%。25H1持续经营业务之经营溢利13亿，同比+9%，专业运动分部的 经营溢利0.8亿，同比大幅增长237%。已终止经营业务(K•SWISS和帕拉丁)于2024年上半年亏损1.1亿人 民币后，25H1公司普通股股权持有人应占溢利9亿同比+21.5%。25H1资产负债表保持稳健，现金状况 良好。现金及现金等价物净额19亿，同比+94%。董事会宣派中期股息18.0港仙，派息比率为50.0%。截 至2025年6月30日，集团于中国内地及海外分别共有6360家特步成人店铺及1564家特步少年店铺。索康 尼在中国内地有155家店铺。 户外方面，公司拓展产品矩阵，推出两款高性能产品，分别是"飞石"徒步鞋及涼鞋，以及"山猫"越野跑 鞋。篮球方面，品牌代言人林书豪在沈阳开展一系列活动，包括特步沈阳店的开业、门店签售活动，以 及东北大学互动篮球赛;此外，特步还成为第七届亚洲大学生三对三篮球锦标赛赛事指定转杯赞助商。 智通财经APP获悉，天风证券发布研报称，维持特步国际(01368)"买入 ...